Navigation Links
GenVec Receives National Cancer Institute Grant to Expand Cancer Program
Date:9/30/2009

GAITHERSBURG, Md., Sept. 30 /PRNewswire-FirstCall/ -- GenVec, Inc. (Nasdaq: GNVC) announced today that it has received a Phase I Small Business Innovation and Research (SBIR) grant from the National Cancer Institute (NCI) of the National Institutes of Health (NIH) to support the research of a new approach to treating metastatic cancer. Under this grant, valued at over $300,000, GenVec will investigate the hypothesis that the delivery of a specific gene will stimulate an antitumor response that could control cancer metastases.

(Logo: http://www.newscom.com/cgi-bin/prnh/20081205/DC50112LOGO )

"Funding from this grant provides GenVec with an opportunity to expand our cancer program and explore a novel approach to cancer treatment," said Dr. Douglas Brough, GenVec's Executive Director, Head of Research. "The work expected to be conducted under this grant will explore new ways to control metastases, addressing a severely unmet medical need."

About GenVec

GenVec, Inc. is a biopharmaceutical company developing novel therapeutic drugs and vaccines. GenVec's lead product, TNFerade(TM), is currently in a pivotal clinical study (PACT) in locally advanced pancreatic cancer. TNFerade has also been and is currently being evaluated for its potential use in the treatment of several other cancers, including esophageal cancer, rectal cancer, and head and neck cancer. GenVec also uses its proprietary adenovector technology to develop vaccines for infectious diseases including HIV, malaria, foot-and-mouth disease, respiratory syncytial virus (RSV), and HSV-2. Additional information about GenVec is available at www.genvec.com and in the company's various filings with the Securities and Exchange Commission.

    Investor Contact:           Media Contact:
    GenVec, Inc.                Tiberend Strategic Advisors, Inc.
    Danielle M. DiPirro         Andrew Mielach
    (301) 944-1877              (212) 827-0020
    ddipirro@genvec.com         amielach@tiberendstrategicadvisors.com

SOURCE GenVec, Inc.


'/>"/>
SOURCE GenVec, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. GenVec Announces Multiple Presentations at the American Society of Tropical Medicine and Hygiene Meeting
2. Reclast(R) Receives US FDA Approval as First and Only Once-Yearly Treatment for Women With Postmenopausal Osteoporosis
3. Indevus Receives Approvable Letter From FDA for VALSTAR(R) for Bladder Cancer Therapy
4. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
5. Abbott Receives Supplemental FDA Approval for its Best-in-Class in Sensitivity RealTime HIV-1 Viral Load Test
6. GlaxoSmithKline Receives New HHS Order for H5N1 Bulk Antigen. First North American Clinical Trials with GSKs Candidate Pre-pandemic Flu Vaccine to Start.
7. CryoCor Receives FDA Approval for Right Atrial Flutter
8. Ranbaxy Receives Approval to Manufacture and Market Hydrocodone Bitartrate and Acetaminophen Tablets USP
9. Dimericine(R) Receives FDA Fast Track Designation for Treatment Of Photosensitivity in XP Patients
10. Poniard Pharmaceuticals Receives FDA Fast Track Designation for Picoplatin for Treatment of Small Cell Lung Cancer
11. Kosan Receives Completed Special Protocol Assessment for TIME-1 Pivotal Phase 3 Trial of Tanespimycin in Multiple Myeloma
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/24/2017)... YORK , Jan. 23, 2017 ... long way from conventional syringes with vials to ... systems. These modern devices have become preferred devices ... for prefilled syringes has been rising strongly over ... healthcare facilities are now adopting this format for ...
(Date:1/24/2017)... LONDON , Jan. 23, 2017 Scope ... Care Market with Focus on Intermittent Catheter Market (2016-2020)", ... market by value, by population, by product line. The ... market by value. The report provides a regional ... North America , Europe ...
(Date:1/24/2017)... COTTAGE, New York , January 23, 2017 /PRNewswire/ ... to Witness Sluggish Growth A ... are derived from formulating Active Pharmaceutical Ingredients (API), and ... propanol and propylene glycol. Production of pharmaceutical ... Asia-Pacific excluding Japan ...
Breaking Medicine Technology:
(Date:1/24/2017)... ... January 23, 2017 , ... ... 140 Buzzies users who entered metrics into the product’s app. The data ... new data showed that within just 30 seconds of using Buzzies, people experienced ...
(Date:1/24/2017)... ... January 24, 2017 , ... The National Council of Alcoholism and Drug ... awareness, have worked with communities to designate the last full week of January as ... theme is “Shatter the Myths.” As a community, we can advocate for effective ...
(Date:1/23/2017)... CA (PRWEB) , ... January ... ... provider of translation and localization services for life science companies, has achieved ... inspection organization, TÜV SÜD America. ISO 17100 is the globally recognized standard ...
(Date:1/23/2017)... ... January 23, 2017 , ... ... training standards for healthcare treatment providers who treat the full spectrum of eating ... , The Presidents Council consists of the leading eating disorder treatments centers ...
(Date:1/23/2017)... , ... January 23, 2017 , ... Sharon Kleyne, America’s ... air to educate listeners about the benefits of making new water infrastructure a number ... said, “it’s appropriate that we expect water infrastructure to become a top priority of ...
Breaking Medicine News(10 mins):